New drug ST101 tested in patients with advanced cancers

NCT ID NCT04478279

First seen Feb 15, 2026 · Last updated May 12, 2026 · Updated 15 times

Summary

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate cancer are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University

    New York, New York, 10032, United States

  • Duke University School of Medicine

    Durham, North Carolina, 27708, United States

  • Edinburgh Cancer Centre

    Edinburgh, EH4 2SP, United Kingdom

  • Northwestern Medicine Cancer Centers

    Warrenville, Illinois, 60555, United States

  • START Midwest

    Grand Rapids, Michigan, 49503, United States

  • Sarah Cannon Research Institute

    Denver, Colorado, 80218, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon Research Institute UK

    London, W1G 6AD, United Kingdom

  • The Beaston West of Scotland Cancer Centre

    Glasgow, G12 0YN, United Kingdom

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • University of Leeds

    Leeds, LS9 7TF, United Kingdom

Conditions

Explore the condition pages connected to this study.